Collecting ECG data and patient insights on heart failure care
An Observational Study to Collect High Resolution 12-Lead Electrocardiogram (ECG) Data for the Development of an ECG Library to Support the Development of a Tool to Monitor Disease Progression, Gather Patient Perspectives on Standard of Care Heart Failure Procedures and Facilitate Familiarity with the Clinical Trial Environment in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction
This study is collecting heart monitoring data and patient feedback from people with heart failure to help improve future heart disease research and treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 45 Years to 80 Years |
| Sex | All |
| Sponsor | Richmond Pharmacology Limited Industry-sponsored |
| Locations | 2 sites (London, London and 1 other locations) |
| Trial ID | NCT06809686 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a high-resolution electrocardiogram (ECG) data library to support future heart disease research. Patients with heart failure will undergo clinical assessments, and their ECGs will contribute to this library. The study also seeks to gather patient perspectives on current standard care and routine diagnostic procedures, which will inform the design of future heart failure trials. Participants may provide feedback on study designs and receive updates on new therapy options.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 45 to 80 diagnosed with heart failure with mildly reduced or preserved ejection fraction.
Not a fit: Patients with conditions that pose undue risk or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of heart failure care and improve patient engagement in future clinical trials.
How similar studies have performed: Other studies have successfully utilized patient insights and ECG data to improve heart disease management, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female participants aged 45 to 80 years (inclusive) at the date of signing the informed consent. 2. Diagnosed with heart failure. 3. Able and willing to provide informed consent to participate. Exclusion Criteria: 1. Diagnostic test results positive for: 1. HIV-1 or HIV-2 infection 2. Hepatitis B or Hepatitis C infection 2. Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or cooperation during the study as judged by the Investigator. 3. Any condition judged by the Investigator to pose an undue risk while participating in the trial 4. Diagnostic results which are inconsistent with heart failure with mildly reduced or preserved ejection fraction as judged by the Investigator.
Where this trial is running
London, London and 1 other locations
- Richmond Pharmacology — London, London, United Kingdom (Recruiting)
- Richmond Pharmacology — London, London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Principal Investigator — Richmond Pharmacology
- Study coordinator: Volunteer Recruitment Team
- Email: volunteer@richmondpharmacology.com
- Phone: +44 (0) 207 042 5800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.